Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.

Kho Y, Jansman FG, Prins NH, Neef C, Brouwers JR.

Ther Drug Monit. 2006 Apr;28(2):206-11.

PMID:
16628132
2.

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.

Anticancer Drugs. 2009 Jun;20(5):396-402. doi: 10.1097/CAD.0b013e32832a2dc1.

PMID:
19287306
3.

Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.

Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L, Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V.

J Gastrointestin Liver Dis. 2009 Mar;18(1):39-43.

4.

Population pharmacokinetics of oxaliplatin in patients with metastatic cancer.

Bastian G, Barrail A, Urien S.

Anticancer Drugs. 2003 Nov;14(10):817-24.

PMID:
14597876
5.

Population pharmacokinetics of oxaliplatin.

Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E.

Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. Epub 2002 Dec 4.

PMID:
12647013
6.

Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.

Zhou H, Choi L, Lau H, Bruntsch U, Vries EE, Eckhardt G, Oosterom AT, Verweij J, Schran H, Barbet N, Linnartz R, Capdeville R.

J Clin Pharmacol. 2000 Mar;40(3):275-83.

PMID:
10709156
7.

[A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer].

Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T.

Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. Japanese.

PMID:
17301527
8.

Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.

Yamada Y, Ohtsu A, Boku N, Miyata Y, Shimada Y, Doi T, Muro K, Muto M, Hamaguchi T, Mera K, Yano T, Tanigawara Y, Shirao K.

Jpn J Clin Oncol. 2006 Apr;36(4):218-23.

PMID:
16684860
9.

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.

Sandström M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO.

Cancer Chemother Pharmacol. 2006 Aug;58(2):143-56. Epub 2006 Feb 8.

PMID:
16465545
10.

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.

Jpn J Clin Oncol. 2007 Sep;37(9):686-91. Epub 2007 Aug 24.

PMID:
17720736
11.

Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.

Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, Poole M, Pescatore SL, Luo FR, Chaney SG.

Anticancer Res. 2002 Jul-Aug;22(4):2301-9.

PMID:
12174918
12.

Oxaliplatin pharmacokinetics during a four-hour infusion.

Kern W, Braess J, Böttger B, Kaufmann CC, Hiddemann W, Schleyer E.

Clin Cancer Res. 1999 Apr;5(4):761-5.

13.

A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.

Xiong JP, Zhang L, Zhong LX, Qiu F, Xu J, Tao QS, Xiang XJ, Yu F, Tang XM.

Anticancer Drugs. 2007 Oct;18(9):1103-7.

PMID:
17704661
14.

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.

Joel SP, Papamichael D, Richards F, Davis T, Aslanis V, Chatelut E, Locke K, Slevin ML, Seymour MT.

Clin Pharmacol Ther. 2004 Jul;76(1):45-54.

PMID:
15229463
15.

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group.

J Clin Oncol. 2006 Aug 1;24(22):3562-9.

PMID:
16877722
17.

Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.

Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M.

Ann Surg Oncol. 2008 Jan;15(1):219-26. Epub 2007 Sep 26.

PMID:
17896145
18.

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.

Caponigro F, Lacombe D, Twelves C, Bauer J, Govaerts AS, Marréaud S, Milano A, Anthoney A.

Eur J Cancer. 2009 Jan;45(1):48-55. doi: 10.1016/j.ejca.2008.08.011. Epub 2008 Sep 20.

PMID:
18809314
19.

The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.

Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.

Gan To Kagaku Ryoho. 2009 May;36(5):797-801.

PMID:
19461180
20.

Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.

Cho HK, Lee ES, Lee JW, Park JK, Kang JH, Lee KS, Shim CK, Chung SJ, Kim DD, Kuh HJ.

J Cancer Res Clin Oncol. 2006 May;132(5):320-6. Epub 2006 Jan 4.

PMID:
16395593

Supplemental Content

Support Center